Alzamend Neuro, Inc. (ALZN) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US02262M6057
Alzamend Neuro, Inc. financials
| Fiscal year | 2025 | 2026 |
|---|---|---|
| Operating income | -4.50 m USD | -8.77 m USD |
| EBIT | -4.50 m USD | -8.77 m USD |
| Net income | -4.51 m USD | -8.77 m USD |
| Diluted EPS – continuing operations | -11.32 USD | -2.63 USD |
Full history since 2019, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Alzamend Neuro, Inc.
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
More stocks
- Mag Mile Capital, Inc. (MMCP)
- Sonendo, Inc. (SONX)
- EMERSON RADIO CORP (MSN)
- NATURAL ALTERNATIVES INTERNATIONAL INC (NAII)
- GridAI Technologies Corp. (GRDX)
- Zoned Properties, Inc. (ZDPY)
- FLYWHEEL ADVANCED TECHNOLOGY, INC. (FWFW)
- NORTHERN MINERALS & EXPLORATION LTD. (NMEX)
- Aprea Therapeutics, Inc. (APRE)
- Purple Innovation, Inc. (PRPL)
- GAXOS.AI INC. (GXAI)
- BAB, INC. (BABB)
Not investment advice. All data without warranty, price as of 12.11.2026. Details in the risk notice.